FAQ: Alpha Cognition's $35 Million Oversubscribed Public Offering and ZUNVEYL Commercialization
Summary
Alpha Cognition Inc. has priced an oversubscribed public offering of 5.6 million shares at $6.25 per share, raising approximately $35 million in gross proceeds. The funds will be used to accelerate commercialization of ZUNVEYL, their Alzheimer's disease treatment, including sales expansion, marketing, and reimbursement infrastructure.
What is the main purpose of Alpha Cognition’s public offering?
The primary purpose is to raise approximately $35 million in gross proceeds to accelerate commercialization of ZUNVEYL (Benzgalantamine), including sales expansion, marketing, payer coverage, and reimbursement infrastructure for their Alzheimer’s disease treatment.
How many shares were offered and at what price?
Alpha Cognition offered 5.6 million common shares (or pre-funded warrants in lieu thereof) at $6.25 per share, with Titan Partners Group having a 30-day option to purchase up to an additional 840,000 shares to cover over-allotments.
Why is this offering significant for Alpha Cognition?
This oversubscribed offering provides critical funding to maximize near-term adoption of ZUNVEYL while laying the foundation for long-term growth, according to CEO Michael McFadden, supporting the company’s commercialization efforts for their neurodegenerative disease treatments.
What is ZUNVEYL and what conditions does it treat?
ZUNVEYL is a patented drug approved as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. It’s also being developed for Cognitive Impairment with mild Traumatic Brain Injury (mTBI).
How does ZUNVEYL differ from other Alzheimer’s treatments?
ZUNVEYL’s active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition, and it’s expected to have minimal gastrointestinal side effects.
Who is managing the public offering?
Titan Partners Group, a division of American Capital Partners, is acting as sole bookrunner for the offering and has been granted a 30-day option to purchase additional shares to cover over-allotments.
Where can I find more information about Alpha Cognition?
For more information, visit the company’s website at https://www.alphacognition.com/ or view the full press release at https://ibn.fm/Zsy1b.
What other treatments is Alpha Cognition developing?
In addition to ZUNVEYL for Alzheimer’s disease, Alpha Cognition is developing ALPHA-1062 in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mild Traumatic Brain Injury (mTBI).
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 242858